In this guide
Tesamorelin is a stabilized analog of growth-hormone-releasing hormone (GHRH). Like other GHRH analogs, it prompts the pituitary to release the body's own growth hormone — but it occupies a distinct place in the literature because its research is unusually focused on one outcome: the reduction of visceral adipose tissue, the deep abdominal fat that surrounds the organs.
How the mechanism works
Tesamorelin binds the GHRH receptor on the pituitary, the same target as CJC-1295, and stabilizing modifications let it survive in circulation long enough to produce a meaningful signal. The result is elevated growth hormone and, downstream, IGF-1. What sets its research profile apart isn't the receptor — it's where the studies have concentrated the outcome measures.
Why its research centers on visceral fat
Tesamorelin is the GHRH analog most associated with visceral fat and body-composition research. It is also the version of this molecule that has been through formal clinical development: a stabilized GHRH analog was studied in controlled trials and documented for its metabolic effects on visceral abdominal fat, including a well-known trial published in the New England Journal of Medicine in 2007.1 Because of that clinical record, tesamorelin is a common reference compound in research on visceral adiposity, and it also appears in studies touching liver fat and related metabolic markers.
How it compares to CJC-1295
Both tesamorelin and CJC-1295 are GHRH analogs that work on the same receptor, so the difference is one of research emphasis rather than mechanism. CJC-1295's literature skews toward sustained GH and IGF-1 elevation in general; tesamorelin's skews toward visceral-fat and body-composition outcomes specifically. Researchers studying the GH axis broadly often reach for CJC-1295; those studying it through a metabolic, adiposity lens often reach for tesamorelin. Both sit within the wider growth-hormone axis we map elsewhere.
Studying the GH axis and body composition? Tesamorelin is available in multiple research vial sizes, third-party tested, with a published COA.
View TesamorelinFrequently asked questions
What is Tesamorelin? A stabilized GHRH analog that prompts pituitary GH release, most studied for its effects on visceral fat and body composition.
How is it different from CJC-1295? Same receptor, different research emphasis — tesamorelin's literature centers on visceral fat, CJC-1295's on sustained GH/IGF-1 signaling.
Is Tesamorelin approved for human use? A pharmaceutical version has been through clinical development for a specific medical indication, but the compound sold here is supplied strictly for in-vitro research and laboratory use only and is not intended for human consumption.
Research references
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. PubMed ↗
For in-vitro research and laboratory use only. Not for human consumption. References are provided for scientific context and do not constitute a product claim.